Newswire (Published: Friday, August 16, 2019, Received: Friday, August 16, 2019, 5:36:07 PM CDT)

Word Count: 501

2019 AUG 16 (NewsRx) -- By a News Reporter-Staff News Editor at Clinical Trials Daily -- A new study on Oncology - Prostate Cancer is now available. According to news reporting from Tampa, United States, by NewsRx journalists, research stated, “Integration of evolutionary dynamics into systemic therapy for metastatic cancers can prolong tumor control compared with standard maximum tolerated dose (MTD) strategies. Prior investigations have focused on monotherapy, but many clinical cancer treatments combine two or more drugs.”

Financial support for this research came from NIH NCI.

The news correspondents obtained a quote from the research from H. Lee Moffitt Cancer Center and Research Institute, “Optimizing the evolutionary dynamics in multidrug therapy is challenging because of the complex cellular interactions and the large parameter space of potential variations in drugs, doses, and treatment schedules. However, multidrug therapy also represents an opportunity to further improve outcomes using evolution-based strategies. We examine evolution-based strategies for two-drug therapy and identify an approach that divides the treatment drugs into primary and secondary roles. The primary drug has the greatest efficacy and/or lowest toxicity. The secondary drug is applied solely to reduce the resistant population to the primary drug. Simulations from the mathematical model demonstrate that the primary-secondary approach increases time to progression (TTP) compared with conventional strategies in which drugs are administered without regard to evolutionary dynamics. We apply our model to an ongoing adaptive therapy clinical trial of evolution-based administration of abiraterone to treat metastatic castrate-resistant prostate cancer. Model simulations, parameterized with data from individual patients who progressed, demonstrate that strategic application of docetaxel during abiraterone therapy would have significantly increased their TTP. Mathematical models can integrate evolutionary dynamics into multidrug cancer clinical trials.”

According to the news reporters, the research concluded: “This has the potential to improve outcomes and to develop clinical trials in which these mathematical models are also used to estimate the mechanism(s) of treatment failure and explore alternative strategies to improve outcomes in future trials.”

For more information on this research see: Multidrug Cancer Therapy In Metastatic Castrate-resistant Prostate Cancer: an Evolution-based Strategy. Clinical Cancer Research, 2019;25(14):4413-4421. Clinical Cancer Research can be contacted at: Amer Assoc Cancer Research, 615 Chestnut St, 17TH Floor, Philadelphia, PA 19106-4404, USA. (American Association for Cancer Research -; Clinical Cancer Research -

Our news journalists report that additional information may be obtained by contacting R.A. Gatenby, H. Lee Moffitt Cancer Center and Research Institute, Integrated Math Oncol Dept, Tampa, FL, United States. Additional authors for this research include J.B. West, M.N. Dinh, J.S. Brown, A.R. Anderson and J.S. Zhang.

The direct object identifier (DOI) for that additional information is: This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

(Our reports deliver fact-based news of research and discoveries from around the world.)


H. Lee Moffitt Cancer Center and Research Institute Inc.
American Association for Cancer Research


North America
United States


Science and Technology
      Scientific Research
            Medical Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Medicinal Drugs